Prime Genomics, Inc.

San Francisco, CA · Founded 2011 · Medtech · Defunct

Saliva-based liquid biopsy diagnostic test using cell-free RNA and proprietary algorithms to screen for breast cancer

Claim this profile

Follows are private to you and power your alerts

Updated · primegenomics.com

Sector
Medtech
Headquarters
San Francisco, CA
Founded
2011
Latest Form D
$20K, Dec 2012
Total capital
$512K
Federal grants
$300K
1 award · 2019
Rank in peer group#3 of 68
Private capital raised
$212K
2 Form D · last Dec 2012
167 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
6 pending

Capital timeline

20112013201520172019FEDERAL ↑EQUITY ↓Cumulative $512K$300K1st Form D$192K2nd Form D$20K
20112013201520172019FEDERAL ↑EQUITY ↓Cumulative $512K$300K2nd Form D$20K

Latest events

  • Federal grantHealth and Human S · Phase I · A Noninvasive, Precision Medicine Approach to Improve Breast Cancer Screening Using Cell-free RNA from Saliva.$300K
  • Private capital raisedForm D · SEC · 2nd filing$20K
  • Private capital raisedForm D · SEC · 1st filing$192K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 68 peers

Line = median

Medtech · Instrument

  • Federal grants#3 · top 4%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • ALAN R. BRIMMPromoterNamed in SEC Form D filings
  • PETER V. GROETZINGERPromoterNamed in SEC Form D filings
  • ROBERT R. TUFTSDirector, PromoterNamed in SEC Form D filings
  • SANDY C. SHAWExecutive Officer, Director, PromoterNamed in SEC Form D filings
  • SCOTT R. GREENSTONEDirectorNamed in SEC Form D filings
  • THOMAS W LOKERExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 6
  • PendingMethods For Cancer DetectionUSPTOApplication 16462699
  • PendingSystem For The Quantification Of System-wide Dynamics In Complex NetworksUSPTOApplication 16298557
  • PendingSystem for the Quantification of System-Wide Dynamics in Complex NetworksUSPTOApplication 14991502
Show all 6 patent records
  • Methods For Cancer DetectionMar 12, 2020 · Application 16462699Pending
  • System For The Quantification Of System-wide Dynamics In Complex NetworksNov 7, 2019 · Application 16298557Pending
  • System for the Quantification of System-Wide Dynamics in Complex NetworksApr 28, 2016 · Application 14991502Pending
  • Methods For Cancer DetectionApplication PCTUS2017063157Pending
  • Methods For Cancer DetectionApplication 62425549Pending
  • System For The Quantification Of System-wide Dynamics In Complex NetworksApplication PCTUS2011001184Pending

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .